Wealth Enhancement Advisory Services
GLUE icon

Wealth Enhancement Advisory Services’s Monte Rosa Therapeutics GLUE Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$597K Sell
25,921
-1,156
-4% -$21.8K ﹤0.01% 2519
2026
Q1 		$463K Buy
27,077
+4,788
+21% +$91.6K ﹤0.01% 2379
2025
Q4 		$357K Buy
22,289
+3,746
+20% +$50.5K ﹤0.01% 2768
2025
Q3 		$137K Sell
18,543
-1,464
-7% -$7.75K ﹤0.01% 3259
2025
Q2 		$97.4K Buy
+20,007
New +$89.2K ﹤0.01% 3140

Other funds holding GLUE

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
MFA
Mayflower Financial Advisors Boston, Massachusetts $1.16B AUM 24.36% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
DWM
Dogwood Wealth Management Lenexa, Kansas $253M AUM 19.41% 1-Year Est. Return

Wealth Enhancement Advisory Services's GLUE Position: Q2 2026 in Review

Wealth Enhancement Advisory Services reduced its Monte Rosa Therapeutics (GLUE) stake by 4.3% in Q2 2026, selling an estimated $21.8K and leaving 25,921 shares worth $597K. The position accounts for ﹤0.01% of the portfolio, ranked #2519.

Wealth Enhancement Advisory Services first reported a position in GLUE in Q2 2025 and has held it in 5 quarters since. 8 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Wealth Enhancement Advisory Services held 25,921 shares of Monte Rosa Therapeutics worth $597K as of Q2 2026.
  • Wealth Enhancement Advisory Services sold 1,156 Monte Rosa Therapeutics shares in Q2 2026, an estimated $21.8K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #2519 holding.
  • Wealth Enhancement Advisory Services first reported a position in Monte Rosa Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 8 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.